CoChat
Sign Up
Cited by 163Multiple Sclerosis Research StudiesMedical Coding and Health InformationChronic Disease Management Strategies

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance

Open access
for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis, Marrie, Ruth Ann, Fisk, John D, Yu, Bo Nancy, Leung, Stella, Elliott, Lawrence, Caetano, Patricia, Warren, Sharon, Evans, Charity, Wolfson, Christina, Svenson, Lawrence W, Tremlett, Helen, Blanchard, James F, Patten, Scott B·2013·BMC Neurology
DOI 10.1186/1471-2377-13-16PMC PMC3599013
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: While mental comorbidity is considered common in multiple sclerosis (MS), its impact is poorly defined; methods are needed to support studies of mental comorbidity. We validated and applied administrative case definitions for any mental comorbidities in MS. METHODS: Using administrative health data we identified persons with MS and a matched general population cohort. Administrative case definitions for any mental comorbidity, any mood disorder, depression, anxiety, bipolar disorder and schizophrenia were developed and validated against medical records using a a kappa statistic (k). Using these definitions we estimated the prevalence of these comorbidities in the study populations. RESULTS: Compared to medical records, administrative definitions showed moderate agreement for any mental comorbidity, mood disorders and depression (all k ≥ 0.49), fair agreement for anxiety (k = 0.23) and bipolar disorder (k = 0.30), and near perfect agreement for schizophrenia (k = 1.0). The age-standardized prevalence of all mental comorbidities was higher in the MS than in the general populations: depression (31.7% vs. 20.5%), anxiety (35.6% vs. 29.6%), and bipolar disorder (5.83% vs. 3.45%), except for schizophrenia (0.93% vs. 0.93%). CONCLUSIONS: Administrative data are a valid means of surveillance of mental comorbidity in MS. The prevalence of mental comorbidities, except schizophrenia, is increased in MS compared to the general population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2377-13-16

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Age-specific prevalence of mental comorbidity in the MS (A) and general populations (B). Administrative case definitions used:Omnibus ≥ 1 Hospital or ≥ 5 Physician OR (≥ 1 Physician AND ≥ 4 Prescription claims) in 2 years. Mood disorder ≥ 1 Hospital or ≥ 5 Physician OR (≥ 1 Physician AND ≥ 4 Prescription) in 2 years. Depression ≥ 1 Hospital or ≥ 5 Physician OR (≥ 1 Physician AND ≥ 7 Prescription) in 2 years. Anxiety ≥ 1 Hospital or ≥ 2 Physician OR (≥ 1 Physician AND ≥ 2 Prescription) in 2 years. Bipolar disorder ≥ 1 Hospital or ≥ 3 Physician OR (≥ 1 Physician AND ≥ 3 Prescription) in 5 years. Schizophrenia ≥ 1 Hospital or ≥ 2 Physician in 2 years.
Figure 1 Age-specific prevalence of mental comorbidity in the MS (A) and general populations (B). Administrative case definitions used:Omnibus ≥ 1 Hospital or ≥ 5 Physician OR (≥ 1 Physician AND ≥ 4 Prescription claims) in 2 years. Mood disorder ≥ 1 Hospital or ≥ 5 Physician OR (≥ 1 Physician AND ≥ 4 Prescription) in 2 years. Depression ≥ 1 Hospital or ≥ 5 Physician OR (≥ 1 Physician AND ≥ 7 Prescription) in 2 years. Anxiety ≥ 1 Hospital or ≥ 2 Physician OR (≥ 1 Physician AND ≥ 2 Prescription) in 2 years. Bipolar disorder ≥ 1 Hospital or ≥ 3 Physician OR (≥ 1 Physician AND ≥ 3 Prescription) in 5 years. Schizophrenia ≥ 1 Hospital or ≥ 2 Physician in 2 years.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 3

  1. Patten S: Integrating data from clinical and administrative databases in pharmacoepidemiological research. Can J Clin Pharmacol. 1998, 5 (2): 92-97.
  2. Martens P, Fransoo R, McKeen N, Burland E, Jebamani L, Burchill C, Coster CD, Ekuma O, Prior H, Chateau D: Patterns of regional mental illness disorder diagnoses and service use in Manitoba: a population-based study. 2004, Winnipeg: Manitoba Centre for Health Policy, University of Manitoba
  3. Branch HIM: Population report. 2008, Winnipeg, Manitoba: Manitoba Health and Healthy Living

Cited by

Sorted by citations

Items 101–163 of 163

Related

See all

Metadata

Authors
for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis, Marrie, R. A., Fisk, J. D., Yu, B. N., Leung, S., Elliott, L., Caetano, P., Warren, S., Evans, C., Wolfson, C., Svenson, L. W., Tremlett, H., Blanchard, J. F., & Patten, S. B.
Affiliations
  • University of Manitoba (CA)
  • Health Sciences Centre (CA)
  • Dalhousie University (CA)
  • University of Alberta (CA)
  • University of Saskatchewan (CA)
  • Alberta Health (CA)
  • Research Institute of the McGill University Health Centre (CA)
Corresponding author
Marrie, Ruth Ann
ORCID
Venue
BMC Neurology
Publisher
Springer Science and Business Media LLC
Published
2013-02-06
Volume
13
Issue
1
Pages
16-16
ISSN
1471-2377 (ISSN-L)
DOI
10.1186/1471-2377-13-16
PMC
PMC3599013
OpenAlex
W2011332759
Cited by
163
References
34
Citations by year
2026: 8 · 2025: 11 · 2024: 13 · 2023: 11 · 2022: 10 · 2021: 14 · 2020: 10 · 2019: 11 · 2018: 15 · 2017: 12 · 2016: 16 · 2015: 19 · 2014: 11 · 2013: 2
FWCI
11.99
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Neurology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • cIRcle (University of British Columbia) (submittedVersion, cc-by)
  • Mspace (University of Manitoba) (submittedVersion)
  • Open Collections
Funders
  • United States Agency for International Development
  • Bill and Melinda Gates Foundation
  • Amgen
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Biogen
  • Teva Pharmaceutical Industries
  • Alberta Health Services
  • Health Sciences Centre Foundation
  • McGill University
  • European Committee for Treatment and Research in Multiple Sclerosis
  • Manitoba Health Research Council
  • Canadian Health Services Research Foundation
  • Public Health Agency of Canada
  • University of Alberta
  • Michael Smith Health Research BC (MOP-93646, RG 4202-A-2)
  • Multiple Sclerosis Society of Canada (MOP-93646, RG 4202-A-2)
  • Multiple Sclerosis Society
  • Public Health Agency
  • Dalhousie University
  • University of British Columbia
  • Schweizerische Multiple Sklerose Gesellschaft
  • Alberta Innovates
  • Servier
  • H. Lundbeck A/S
  • Bayer Canada
  • Canadian Institutes of Health Research (RG 4202-A-2, (MOP: #93646, 190898)
  • Social Sciences and Humanities Research Council of Canada (93646)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Health Sciences › Health Professions › Health Information Management › Medical Coding and Health Information
  • Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
Keywords
multiple sclerosis, psychiatric comorbidity, administrative data validation, case definition, depression, anxiety, bipolar disorder, schizophrenia, mood disorders, prevalence, population-based surveillance
MeSH terms
Adult, Mental Disorders, Canada, Female, Humans, Male, Medical Records, Middle Aged, Multiple Sclerosis, Population Surveillance, Reproducibility of Results, Cohort Studies, Comorbidity, Prevalence, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review